4basebio AG signs term sheet for investment in nanoparticle-based gene therapy delivery technology

Public disclosure of inside information according to article 17 MAR

Heidelberg (pta033/24.09.2020/16:15) – Heidelberg, Germany, and Cambridge, United Kingdom, 24 September 2020 4basebio AG (formerly Expedeon AG) (Frankfurt: 4BSB; ISIN: DE000A2YN801; Prime Standard) announces its subsidiary 4basebio Limited has agreed heads of terms with a view to investing up to Eur5m in the development and commercialisation of a non-viral gene therapy delivery platform. If the transaction is concluded on the proposed terms, 4basebio will hold a 50% economic stake in the venture and become its exclusive supplier of DNA products.

Subject to contract and due diligence, the initial binding commitment will be for 4basebio to invest Eur2m, with the remaining investment discretionary. The transaction is expected to close before the end of the year.

For further information please contact:

Dr Heikki Lanckriet

CEO/CSO

T: +44 1223 873 364

email: heikki.lanckriet@4basebio.com

Dr. Robert Mayer

Manager IR

phone: +49 171 3876540

Email: robert.mayer@4basebio.com

 

(end)

emitter: 4basebio AG

address: Waldhofer Str. 102, 69123 Heidelberg

country: Germany

contact person: Robert Mayer

phone: +49 171 3876540

e-mail: robert.mayer@4basebio.com

website: investors.4basebio.com

ISIN(s): DE000A2YN801 (share)

stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf; open market in Berlin, Tradegate

[ source: http://www.pressetext.com/news/20200924033 ]